Muriel Habibian

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly et al. · The Lancet Oncology · 2013 · 727 citations

Androgen-deprivation Therapy, Urology, Genitourinary Cancer +7

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Gwénaëlle Gravis, Jean‐Marie Boher, Florence Joly et al. · European Urology · 2015 · 454 citations

Urology, Genitourinary Cancer, Getug-afu15 Trial +7

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial

C. Carrié, Ali Hasbini, Guy de Laroche et al. · The Lancet Oncology · 2016 · 356 citations

Urology, Surgical Oncology, Salvage Radiotherapy +8

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Karim Fizazi, Laura Faivre, F. Lesaunier et al. · The Lancet Oncology · 2015 · 236 citations

Urology, Getug 12, Genitourinary Cancer +8

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial

Karim Fizazi, Lance C. Pagliaro, Agnès Laplanche et al. · The Lancet Oncology · 2014 · 197 citations · Full text

Urology, Medicine, Cancer Management +8